Skip to content

Cocaine and Pentoxifylline (BED IN 47)

Targeting Immune Inflammation in Cocaine Use Disorder: A Human Laboratory Study With Pentoxifylline

Status
Recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT07086794
Enrollment
30
Registered
2025-07-25
Start date
2025-11-10
Completion date
2028-02-28
Last updated
2026-06-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cocaine Use Disorder

Brief summary

This will be a human laboratory study evaluating the influence of pentoxifylline treatment on the effects of cocaine. Supported by and included in the Helping to End Addiction Long-term® (HEAL) Initiative.

Interventions

DRUGPlacebo

The effects of placebo will be determined.

The effects of IV Cocaine will be determined.

DRUGPentoxifylline

The effects of pentoxifylline will be determined.

Sponsors

William Stoops
Lead SponsorOTHER
National Institute on Drug Abuse (NIDA)
CollaboratorNIH

Study design

Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
BASIC_SCIENCE
Masking
TRIPLE (Subject, Caregiver, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to 55 Years
Healthy volunteers
Yes

Inclusion criteria

1. able to speak/read English, 2. not seeking treatment for drug use at the time of the study, 3. female or male between the ages of 18 and 55 years, 4. recent smoked or intravenous cocaine use verified by benzoylecgonine positive urine, as well as fulfillment of DSM-5 diagnostic criteria for CUD, 5. judged to be medically and psychiatrically healthy by study physicians other than the diagnosis for CUD at the time of screening, 6. ECG, read by a cardiologist, within normal limits, 7. females using an effective form of birth control and not pregnant or breastfeeding and 8) no known contraindications or allergies to pentoxifylline.

Exclusion criteria

1. unable to speak/read English, 2. seeking treatment for drug use, 3. under 18 years or over 55 years, 4. no recent smoked or intravenous cocaine use as indicated by benzoylecgonine negative urine and no DSM-5 diagnosis of CUD, 5. judged to be medically or psychiatrically unhealthy by study physicians at the time of screening, 6. ECG, read by a cardiologist, outside normal limits, 7. females not using an effective form of birth control or pregnant or breastfeeding, 8. contraindications or allergies to pentoxifylline, and 9. Self-reported history of head trauma, seizure, CNS tumors, or use of concomitant medications that lower seizure threshold, or first-degree family history of seizures.

Design outcomes

Primary

MeasureTime frameDescription
Reinforcing Effects of Cocaine9 times over approximately 1 month inpatient admissionNumber of Times Subjects Choose Cocaine (Maximum of 5 Choices) Over Money

Countries

United States

Contacts

CONTACTWilliam W Stoops, PhD
william.stoops@uky.edu859-257-5388

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Jun 9, 2026